Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):: US0197701065
LEI:
Country:: United States of America
Address:: 210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://allogene.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Mithra Pharmaceuticals S.A. Biotech firm developing pharma for women's health: contraception, fertility, and menopause.	Belgium	MITRA
MIZUHO MEDY CO.,LTD. Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.	Japan	4595
MOA Life Plus Co. Ltd. Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.	South Korea	142760
Moberg Pharma Develops & commercializes a leading topical treatment for nail fungus for European markets.	Sweden	MOB
Mochida Pharmaceutical Co.,Ltd. An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.	Japan	4534
Moderna, Inc. Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.	United States of America	MRNA
MOLECULAR PARTNERS AG Biopharma firm developing novel DARPin® protein therapies for cancer and serious diseases.	United States of America	MOLN
Monopar Therapeutics Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.	United States of America	MNPR
Monte Rosa Therapeutics, Inc. Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.	United States of America	GLUE
Moogene Medi Co., Ltd. Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.	South Korea	322970